Ligand/VEGFR-2 co-expression profiles revealed a nearly uniform distribution for VEGF-D/VEGFR-2 and an accentuated co-reactivity in the tumor budding regions for VEGF-C/VEGFR-2 in the respective metastatic group (Table 2). The gene discussed is KDR; the disease is neoplasm.